Other languages Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E. Other stock markets 02:10:22 2024-05-23 am EDT			5-day change	1st Jan Change
0.34 ^AUD	0.00%		0.00%	+65.85%

May. 01	Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	MT
Apr. 22	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	Apr. 30
Dimerix Raises AU$20 Million for Kidney Disease Study	Mar. 12
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25
Dimerix Limited Announces Appointment of Mark Diamond as Director	Nov. 30
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	Nov. 27
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	Nov. 07
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23-10-22
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	23-10-05
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	23-07-05
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	23-07-02
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	23-05-03
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023	23-04-30
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8%	23-02-16
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial	23-02-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Dimerix Limited

Equities

DXB

AU000000DXB7

Other languages

Filters